Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 29 Nov 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018.
- 24 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
- 24 Aug 2016 Status changed from active, no longer recruiting to recruiting.